1. Pink Sheet

Brazilian HTA To Adopt Cost-Effectiveness Thresholds

 
• By Francesca Bruce

Brazil’s health technology assessment institute is to incorporate cost-effectiveness thresholds into its decision making.

Brazil money and medicines
Brazil moves forward with cost-effectiveness thresholds • Source: Shutterstock

After years of debate, Brazil’s health technology assessment body, CONITEC, has approved a proposal to formally incorporate cost-effectiveness thresholds into its assessments, the health ministry announced on 26 September. The move should ensure that cost-effectiveness becomes a more standard part of the assessments that determine whether a medicine is funded through the national health system, the SUS.

CONITEC was established in 2011. Its recommendations on whether to incorporate a product onto the SUS are based on safety,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

More from Pink Sheet

US FDA To Advisory Committee Industry Reps: Don’t Talk Too Much

 
• By Sue Sutter

Nonvoting industry representative’s presence at Pediatric Advisory Committee meeting was required by statute, the agency said, a de facto acknowledgement that an April directive precluding industry reps from sitting on advisory committees has had little practical effect.

New US FDA Biologics License Pathway Could Be Missing Link To Reduce Animal Testing

 
• By Bridget Silverman

Akin to the 505(b)(2) NDA, a new biologic pathway could reduce the need for animal testing, FDA toxicologist says. Expanded use of generally accepted scientific knowledge (GASK), which few sponsors have attempted despite a 2023 draft guidance, would also help.

Capricor Gets Complete Response For DMD Cell Therapy: Unconvincing Data Or New Attitude At FDA?

 
• By Joseph Haas

Seven weeks before its action date and a month after an advisory committee was hastily cancelled, Capricor gets a CRL for its cell therapy deramiocel in DMD-related cardiomyopathy citing efficacy and manufacturing concerns. It has a Phase III study nearing readout, though.